Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2026

Primary Completion Date

August 1, 2027

Study Completion Date

February 1, 2028

Conditions

Duchenne Muscular Dystrophy (DMD)

Interventions

DRUG

SGLT-2 inhibitor

SGLT-2 inhibitor will be given once daily by mouth

DRUG

SGLT2 inhibitor

SGLT-2 inhibitor will be given once daily by mouth

Trial Locations (1)

Riley Hospital at Indiana University Health, Indianapolis

All Listed Sponsors

lead

Larry W. Markham

OTHER